☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
amgen
Amgen Reports 52 Weeks Data from P-II Trial of Maritide in Obese People with or without Type 2 Diabetes
November 27, 2024
Amgen’s Otezla (Apremilast) is now Accessible in The US to treat Moderate to Severe Pediatric Plaque Psoriasis
August 22, 2024
Amgen’s Blincyto (Blinatumomab) Receives the US FDA’s Approval to Treat B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
June 17, 2024
Amgen Reports the P-III (MITIGATE) Study Data of Uplizna (Inebilizumab-cdon) to Treat Immunoglobulin G4-Related Disease (IgG4-RD)
June 6, 2024
Amgen’s Bkemv (Biosimilar, Soliris) Receives the US FDA’s Approval for PNH & aHUS
May 28, 2024
Amgen’s Imdelltra (Tarlatamab-dlle) Receives the US FDA’s Approval to Treat Extensive-Stage Small Cell Lung Cancer
May 17, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.